Existing ambiguity surrounding the biological role of p-mTOR/mTOR in prostate cancer could explain the limited clinical efficacy of PI3K/AKT/mTOR inhibitors [14,40,41]. The gene discussed is MTOR; the disease is prostate carcinoma.